Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.
INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.
It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemotherapy as a potential first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer.
The biotechnology firm said that the first overall survival results, issued on Nov. 14, 2024, from the trial showed mature data in patients with a minimum follow-up of 22 months achieved a median overall survival of 32.9 months and a 24-month overall survival rate of 81%.
The company's shares rose past 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.